GLP-1 / Metabolic

Semaglutide

FDA approved

Also known as: Ozempic, Wegovy, Rybelsus

The GLP-1 that started it all — weekly injection, durable weight loss, restored insulin signaling.

Open in AppAsk AI Advisor

Mechanism

GLP-1 receptor agonist. The GLP-1 that started it all — weekly injection, durable weight loss, restored insulin signaling. For full mechanism, dosing protocol, and stacking guidance, ask the AI Advisor or open the compound in-app.

Peer-Reviewed Studies (3)

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)

NEJM · 2021

14.9% weight loss vs 2.4% placebo at 68 weeks.

PubMed PMID 33567185 →

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)

NEJM · 2023

20% reduction in MACE over 39.8 months.

PubMed PMID 37952131 →

Semaglutide for Heart Failure with Preserved Ejection Fraction (STEP-HFpEF)

NEJM · 2023

Significant improvement in HFpEF symptoms.

PubMed PMID 37622681 →

Related Compounds

Tirzepatide

The first dual incretin — superior to GLP-1 alone on weight, glucose, and metabolic markers.

Liraglutide

First-generation GLP-1 — daily injection, robust safety record, foundational to the category.

Retatrutide

Triple agonist — three receptors, one molecule, the highest weight loss efficacy ever recorded.

CagriSema

Amylin meets GLP-1 — dual mechanism that addresses what semaglutide alone misses.